Patients with extensive-stage small cell lung cancer (SCLC) experienced clinically meaningful benefits with lurbinectedin ...

Blue nevus is a benign melanocytic lesion whose most frequent variants are dendritic (common) blue nevus and cellular blue nevus. Atypical cellular blue nevus presents an intermediate histopathology ...

In other words, the study shows that people with T2D have fewer healthy mitochondria, the parts of the cell that produce energy, because a certain protein—dynamin-related protein 1, or DRP1—is ...

In a recent study, researchers aimed to evaluate whether and how PFAS affect the second arm of the immune system, the so-called cellular immune response. This is especially important in the case ...

Hirayama and Suzuki [13] examined the histological findings of 450 cases of nevus of Ota and classified the condition according to the distribution of the dermal melanocytes as follows ...

In other words, the study shows that people with T2D have fewer healthy mitochondria, the parts of the cell that produce energy, because a certain protein - dynamin-related protein 1, or DRP1 - is ...

In research published in New Phytologist, investigators reveal that tomato ripening is regulated by the same mechanism that contributes to humans' and animals' life- and health spans. The ...

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced ...

State officials and AstraZeneca marked the opening Monday of a cell therapy facility in Rockville that aims to create pathways to jobs for the state’s STEM professionals. AstraZeneca completed a ...

SEVEN YEARS AFTER HIS INITIAL CHEMOTHERAPY AND STEM CELL TRANSPLANT, IT CAME BACK. MYELOMA IS A DIFFICULT DISEASE TO FIGHT. IT SEEMS LIKE IT ALWAYS COMES BACK. IT’S NOT CURABLE AT THIS POINT.